Subramanian V B, Lahiri A, Paramasivan R, Raftery E B
Lancet. 1980 Apr 19;1(8173):841-4. doi: 10.1016/s0140-6736(80)91351-3.
The efficacy of verapamil (360 mg daily) in the treatment of patients with chronic stable angina pectoris was compared with placebo. 28 patients were studied in a placebo-controlled double-blind crossover trial of 2 weeks each and afterwards on long-term verapamil. Exercise tests were performed at the end f the placebo period, and after 2 weeks and 4 weeks on verapamil. On placebo, angina developed in all 28 patients during treadmill tests; the mean exercise time was 6.6 min (SEM +/- 0.5 min). The mean exercise time increased to 9.2 (+/- 0.8) min at 2 weeks, and 11.2 (+/- 0.8) min at 4 weeks on verapamil. In 15 and 20 patients out of the 28 angina did not develop during treadmill exercise at 2 and 4 weeks respectively. Trinitrin consumption also decreased. There was a significant improvement in ST-segment changes. Constipation (in 7 patients) and reversible PR-interval prolongation (in 2 patients) were the only side effects. No patient had clinical signs of heart-failure. Thus verapamil (360 mg daily) may be useful in the management of chronic stable angina.
将维拉帕米（每日360毫克）治疗慢性稳定型心绞痛患者的疗效与安慰剂进行了比较。28名患者参与了一项安慰剂对照双盲交叉试验，试验为期两周，之后服用长期维拉帕米。在安慰剂期结束时、服用维拉帕米2周和4周后进行运动试验。服用安慰剂时，所有28名患者在跑步机测试中均出现心绞痛；平均运动时间为6.6分钟（标准误±0.5分钟）。服用维拉帕米2周时，平均运动时间增至9.2（±0.8）分钟，4周时为11.2（±0.8）分钟。28名患者中，分别有15名和20名患者在服用维拉帕米2周和4周时的跑步机运动中未出现心绞痛。硝酸甘油的消耗量也有所减少。ST段改变有显著改善。便秘（7例患者）和可逆性PR间期延长（2例患者）是仅有的副作用。没有患者出现心力衰竭的临床体征。因此，维拉帕米（每日360毫克）可能有助于慢性稳定型心绞痛的治疗。
